secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001564590-22-019858
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Q1 net loss $7.3M; Phase 2 CANAL shows 52% placebo-adjusted cough reduction; $55M financing closed
--------------------------------------------------------------------------------

- Q1 2022 net loss $7.3M vs $8.4M prior year; R&D expenses $4.6M down from $5.6M.
- Cash $29.1M at March 31; plus $55M gross from April private placement for Haduvio development.
- Phase 2 CANAL interim (N=26): 77.3% reduction daytime cough vs 25.7% placebo (p<0.0001); enrollment ended early.
- Full CANAL data expected Q3 2022; Phase 2b/3 PRISM (PN) top-line data expected Q2 2022.
- Phase 2b/3 PRISM enrollment completed Jan 2022; data readout anticipated in current quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022019858/0001564590-22-019858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022019858/trvi-8k_20220512.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer